title: [Liquid Biopsy in Multimodal Treatment of Esophageal Carcinoma].
abstract: Predicting and monitoring the treatment response of patients with esophageal carcinoma are important. Molecular analyses of biopsy specimens are useful; however, the characteristics of the biopsy specimen are not similar to those of whole tumors, including metastatic tumors. Therefore, liquid biopsy using blood samples has been applied for the prediction of the tumor stage, sensitivity to radiotherapy, sensitivity to chemotherapy, and recurrent disease. Liquid biopsy is advantageous for monitoring the treatment response and as an objective diagnostic tool; it is cost effective.
authors.affiliation: Dept. of Surgery, School of Medicine, Toho University.
authors.forename: Hideaki
authors.initials: H
authors.lastname: Shimada
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yajima
authors.forename: Yoko
authors.initials: Y
authors.lastname: Oshima
authors.forename: Tatsuki
authors.initials: T
authors.lastname: Nanami
authors.forename: Takashi
authors.initials: T
authors.lastname: Suzuki
authors.forename: Seiko
authors.initials: S
authors.lastname: Otsuka
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood / Q000235:genetics; D001706:Biopsy; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000097:blood / Q000235:genetics / Q000473:pathology* / Q000628:therapy; D006801:Humans; D009154:Mutation; D016159:Tumor Suppressor Protein p53 / Q000097:blood / Q000235:genetics
chemical_list: D014408:Biomarkers, Tumor; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53